We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure
Read MoreHide Full Article
Key Takeaways
ISRG procedures rose 16% as revenue increased 19% to $2.89 billion in the second quarter.
Intuitive Surgical's Ion procedures climbed 36%, with its installed base reaching 1,096 systems.
ISRG faces tariff costs, weaker bariatric demand and margin pressure from newer product mix.
Intuitive Surgical (ISRG - Free Report) is being shaped by more than quarterly revenue growth. The company is tied to wider robotic surgery adoption, expansion into minimally invasive diagnostics and deeper use of software inside hospital programs.
Those themes still come with limits. Tariffs, product mix, hospital spending patterns and shifting procedure demand remain important.
ISRG Benefits From Robotic Care Expansion
Intuitive Surgical remains positioned around the move toward minimally invasive and robot-assisted care. Its da Vinci platform supports procedures across general surgery, urology, gynecology, cardiothoracic care, and head and neck specialties.
Worldwide procedures across da Vinci and Ion rose 16% year over year in second-quarter 2026, including 15% growth for da Vinci. Revenue increased 19% to $2.89 billion, supported by procedure volumes, leasing revenues and installed-base expansion. Medtronic plc (MDT - Free Report) and Johnson & Johnson (JNJ - Free Report) give investors broader medtech comparisons, while ISRG offers a more focused robotic care profile.
Intuitive Surgical Pushes Beyond Surgery With Ion
Ion expands Intuitive Surgical beyond traditional surgery into diagnostic, endoluminal procedures. The flexible, robotic-assisted catheter platform supports minimally invasive lung biopsy, extending the company’s opportunity outside soft tissue surgery. This also helps the company to tap the lucrative lung cancer market.
Ion procedures increased 36% to 48,000 in the quarter, while cumulative procedures exceeded 400,000. Intuitive Surgical placed 55 Ion systems, expanded the Ion installed base 21% year over year to 1,096 systems, and has installed Ion in 12 countries outside the United States.
Software is becoming a larger part of Intuitive Surgical’s platform value. The company began rolling out the first phase of more than 100 da Vinci 5 updates aimed at telepresence, simulation-based training and care-team workflow.
The My Intuitive+ renewal cycle adds another signal. The company executed its first renewals for offerings covering telepresence, simulation and AI-driven case insights, and no customer in the initial cohort opted out. Better training, workflow support and case insights can make the installed base more useful over time.
Intuitive Surgical Faces Cost and Demand Shifts
The trend story is not one-sided. Intuitive Surgical remains exposed to tariffs, freight, semiconductor memory costs and the mix of newer products. Its second-quarter adjusted gross margin was 70%, helped by a $36 million pretax tariff refund. Excluding that benefit, the margin would have been 68.7%.
Management raised its 2026 adjusted gross margin outlook to 68-69%, but the range still includes an estimated tariff impact equal to 1% of revenues. U.S. da Vinci procedures grew 12% in the quarter, down from 14% in the first quarter, as some benign procedures were deferred. Bariatric procedures declined at a high-single-digit rate amid greater GLP-1 use.
What Trend Signals Mean for ISRG
ISRG’s trend profile remains attractive, but not frictionless. Robotics adoption, Ion lung biopsy growth and digital ecosystem development support the expansion case, while tariffs, capital budgets and procedure mix create constraints.
The current operating picture also makes Zacks Rank and Style Scores important for context. Zacks Rank reflects earnings estimate revision trends, while Style Scores help investors evaluate value, growth and momentum characteristics. A favorable combination is most useful when a stock has a top Zacks Rank and stronger Style Scores.
ISRG’s current Zacks Rank #2 (Buy), Value Score of D, Growth Score of B, Momentum Score of A and VGM Score of B should be checked separately. Investors should pair the company’s trend signals with those indicators before deciding whether the setup supports a bullish or selective stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Shutterstock
ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure
Key Takeaways
Intuitive Surgical (ISRG - Free Report) is being shaped by more than quarterly revenue growth. The company is tied to wider robotic surgery adoption, expansion into minimally invasive diagnostics and deeper use of software inside hospital programs.
Those themes still come with limits. Tariffs, product mix, hospital spending patterns and shifting procedure demand remain important.
ISRG Benefits From Robotic Care Expansion
Intuitive Surgical remains positioned around the move toward minimally invasive and robot-assisted care. Its da Vinci platform supports procedures across general surgery, urology, gynecology, cardiothoracic care, and head and neck specialties.
Worldwide procedures across da Vinci and Ion rose 16% year over year in second-quarter 2026, including 15% growth for da Vinci. Revenue increased 19% to $2.89 billion, supported by procedure volumes, leasing revenues and installed-base expansion. Medtronic plc (MDT - Free Report) and Johnson & Johnson (JNJ - Free Report) give investors broader medtech comparisons, while ISRG offers a more focused robotic care profile.
Intuitive Surgical Pushes Beyond Surgery With Ion
Ion expands Intuitive Surgical beyond traditional surgery into diagnostic, endoluminal procedures. The flexible, robotic-assisted catheter platform supports minimally invasive lung biopsy, extending the company’s opportunity outside soft tissue surgery. This also helps the company to tap the lucrative lung cancer market.
Ion procedures increased 36% to 48,000 in the quarter, while cumulative procedures exceeded 400,000. Intuitive Surgical placed 55 Ion systems, expanded the Ion installed base 21% year over year to 1,096 systems, and has installed Ion in 12 countries outside the United States.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. price-consensus-chart | Intuitive Surgical, Inc. Quote
ISRG Turns Software Into a Strategic Asset
Software is becoming a larger part of Intuitive Surgical’s platform value. The company began rolling out the first phase of more than 100 da Vinci 5 updates aimed at telepresence, simulation-based training and care-team workflow.
The My Intuitive+ renewal cycle adds another signal. The company executed its first renewals for offerings covering telepresence, simulation and AI-driven case insights, and no customer in the initial cohort opted out. Better training, workflow support and case insights can make the installed base more useful over time.
Intuitive Surgical Faces Cost and Demand Shifts
The trend story is not one-sided. Intuitive Surgical remains exposed to tariffs, freight, semiconductor memory costs and the mix of newer products. Its second-quarter adjusted gross margin was 70%, helped by a $36 million pretax tariff refund. Excluding that benefit, the margin would have been 68.7%.
Management raised its 2026 adjusted gross margin outlook to 68-69%, but the range still includes an estimated tariff impact equal to 1% of revenues. U.S. da Vinci procedures grew 12% in the quarter, down from 14% in the first quarter, as some benign procedures were deferred. Bariatric procedures declined at a high-single-digit rate amid greater GLP-1 use.
What Trend Signals Mean for ISRG
ISRG’s trend profile remains attractive, but not frictionless. Robotics adoption, Ion lung biopsy growth and digital ecosystem development support the expansion case, while tariffs, capital budgets and procedure mix create constraints.
The current operating picture also makes Zacks Rank and Style Scores important for context. Zacks Rank reflects earnings estimate revision trends, while Style Scores help investors evaluate value, growth and momentum characteristics. A favorable combination is most useful when a stock has a top Zacks Rank and stronger Style Scores.
ISRG’s current Zacks Rank #2 (Buy), Value Score of D, Growth Score of B, Momentum Score of A and VGM Score of B should be checked separately. Investors should pair the company’s trend signals with those indicators before deciding whether the setup supports a bullish or selective stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.